title: Topical ranibizumab as a treatment of corneal neovascularization.
abstract: OBJECTIVE
  To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV).
  
  
  METHODS
  This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA.
  
  
  RESULTS
  Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted.
  
  
  CONCLUSIONS
  Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.
authors: G.B. Bietti Eye Foundation-IRCCS, Rome, Italy. giulio.ferrari@schepens.harvard.edu
authors: Giulio
authors: G
authors: Ferrari
authors: Mohammad H
authors: MH
authors: Dastjerdi
authors: Andre
authors: A
authors: Okanobo
authors: Sheng-Fu
authors: SF
authors: Cheng
authors: Francisco
authors: F
authors: Amparo
authors: Nambi
authors: N
authors: Nallasamy
authors: Reza
authors: R
authors: Dana
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001808:Blood Vessels / Q000187:drug effects / Q000473:pathology; D003315:Cornea / Q000098:blood supply; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D000069579:Ranibizumab; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009883:Ophthalmic Solutions; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab